[ad_1]
We hope to have a final decision in the near future, because in this situation it is very important to assess the situation of the coronavirus in the country, the morbidity and mortality that we monitor every day. These are very important aspects and must be taken into account when making such decisions, ”SAM Chancellor Jurgita Grebenkovien radio told LRT radio on Wednesday.
According to her, several possible solutions are considered, the advantages and disadvantages of each of them are evaluated.
On Monday, Rugilė Pilvinienė, Senior Advisor to the Pharmacovigilance and Poisoning Information Division of the State Medicines Control Agency (VVKT), announced that the first two cases of unusual blood clots had been recorded in Lithuania for people vaccinated with AstraZeneca.
“Thrombocytopenia with thrombosis, namely sagittal sinus thrombosis (the sagittal sinus is a very large vein in the brain) was two cases. Both cases for young people are 27 and 30 years old,” he said.
According to R. Pilvinienė, one person has already recovered, another is still being treated in hospital.
A spokeswoman for the Drug Control Service also said that several more cases of thrombosis were recorded in April.
The European Medicines Agency (EMA) stated in early April that unusual blood clots should be labeled a “very rare” side effect of AstraZeneca’s coronavirus vaccine.
According to the EVA, the benefits of AstraZeneca increase with the age of the vaccinated people and the deterioration of the epidemiological situation in the countries. However, vaccination of younger people ages 20-29 and 30-39 can be reconsidered in light of national morbidity, hospital treatment, and the availability of other vaccines.
[ad_2]
